About Us

Laurus Synthesis is a leading Contract Development & Manufacturing Organization (CDMO) with a solid track record in supporting drug development and manufacturing programs of global pharmaceutical and biotech companies.

Our state of the art facilities in India (Hyderabad and Visakapatnam) and experienced scientific teams have been supporting our customers for over 10 years in meeting the challenges in drug development programs from early phase development to commercial manufacturing. We are part of Laurus Labs — a Fortune 500 India company and one of India's largest and fast-growing pharmaceutical companies. Being part of Laurus Labs helps us leverage the power of rapid, elastic scale and remain consistently dependable.

We are home to 90 Process Development scientists and over 70 Analytical Development scientists having the experience of working on NCE development programs – pre-clinical to commercial. Our team of scientists is complemented by an experienced project management team, which has a strong background in chemistry. Our dedicated project managers serve as single point of contact for customers to enable efficient coordination and service delivery. We have proven expertise in handling successful customer collaborations in the US, Europe, Japan and Asia Pacific.

Two things set us apart: our flexibility in adopting to customer requirements for clinical supplies—process changes, phase-appropriate analytical support, production planning, backward integration of starting materials and QA/QC documentation support; and secondly the integrated nature of our offerings enables us to work with customers at different stages in their drug development and manufacturing journey.

Our diverse customer base ranges from small to mid-sized biotech companies, speciality pharma, as well as some of the world’s largest pharmaceutical firms. Many of these companies have a long association with Laurus Synthesis, given our performance, dependability and an unrivalled culture of quality compliance. We journeyed with several leading clients from the late preclinical stage through to regulatory submission of NCEs and all the way to commercialization.